Boston Scientific Co. (NYSE:BSX) is Brown Lisle Cummings Inc.’s 8th Largest Position

Brown Lisle Cummings Inc. lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 1.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 74,525 shares of the medical equipment provider’s stock after acquiring an additional 833 shares during the quarter. Boston Scientific comprises approximately 2.0% of Brown Lisle Cummings Inc.’s portfolio, making the stock its 8th largest holding. Brown Lisle Cummings Inc.’s holdings in Boston Scientific were worth $6,657,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of BSX. Quarry LP bought a new position in shares of Boston Scientific during the 2nd quarter valued at $33,000. Czech National Bank increased its position in Boston Scientific by 7.1% during the third quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock valued at $25,139,000 after acquiring an additional 19,833 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Boston Scientific by 39.9% in the third quarter. GAMMA Investing LLC now owns 17,432 shares of the medical equipment provider’s stock valued at $1,461,000 after acquiring an additional 4,972 shares during the period. Miracle Mile Advisors LLC boosted its position in Boston Scientific by 4.0% in the third quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock worth $440,000 after purchasing an additional 203 shares during the last quarter. Finally, Bank of New Hampshire grew its stake in shares of Boston Scientific by 52.6% during the 3rd quarter. Bank of New Hampshire now owns 2,235 shares of the medical equipment provider’s stock valued at $187,000 after purchasing an additional 770 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now directly owns 39,398 shares of the company’s stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,989 shares of company stock valued at $2,702,261. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

NYSE BSX opened at $103.11 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 1-year low of $64.08 and a 1-year high of $104.25. The business has a 50 day simple moving average of $93.47 and a two-hundred day simple moving average of $86.33. The stock has a market capitalization of $151.97 billion, a PE ratio of 85.22, a P/E/G ratio of 2.68 and a beta of 0.80.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Canaccord Genuity Group lifted their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. Stifel Nicolaus lifted their target price on Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Finally, Citigroup upped their price target on Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and a consensus price target of $100.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.